GlassScriptPhysician profile
Caroline D Inge
NPI 1538791074
$1,022.05
in general payments reported to CMS, 2019-2025
22 companies · $671 in 2025
The $671 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.55 · 2022: $53.41 · 2023: $13.76 · 2024: $190 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $875.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $170.15 | 2024-2025 | Imfinzi, Tagrisso |
| Merck Sharp & Dohme LLC | $141.97 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Incyte Corporation | $103.08 | 2025 | Monjuvi, Pemazyre, Jakafi |
| Janssen Biotech, INC. | $82.58 | 2024-2025 | Talvey, Darzalex, Rybrevant |
| Takeda Pharmaceuticals U.S.A., INC. | $67.37 | 2025 | Fruzaqla |
| Novocure INC. | $66.31 | 2024-2025 | Optune, Optune Lua (Novottf-200t) |
| Abbvie INC. | $40.85 | 2022 | |
| Medtronic, INC. | $36.87 | 2021 | |
| Jazz Pharmaceuticals INC. | $34.59 | 2025 | |
| Exelixis INC. | $29.94 | 2025 | Cabometyx |
| Axonics, INC. | $26.32 | 2022-2023 | Axonics |
| Sobi, INC | $26.23 | 2024 | |
| Monteris Medical Corporation | $23.75 | 2025 | Neuroblate |
| Genzyme Corporation | $23.59 | 2021 | |
| Aveo Pharmaceuticals, INC. | $23.49 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $22.00 | 2025 | Zoladex |
| Genentech USA, INC. | $19.82 | 2025 | Polivy |
| Sumitomo Pharma America, INC. | $17.33 | 2025 | Orgovyx |
| Myovant Sciences INC. | $17.28 | 2021 | |
| Myriad Genetic Laboratories, INC. | $16.98 | 2024 | Myrisk |
| Boston Scientific Corporation | $15.81 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Inge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.